Indoco Remedies Share Price

Pharmaceuticals company Indoco Remedies announced Q4FY26 & FY26 results Consolidated Financial Highlights: Total Income: The total income for Q4FY26 stood at Rs 47,557 lakh, representing a QoQ growth of 6.55% from Rs 44,634 lakh in Q3FY26 and a YoY increase of 21.25% from Rs 39,223 lakh in Q4FY25. For FY26, total income was Rs 1,84,865 lakh, compared to Rs 1,67,037 lakh in FY25, a growth of 10.67%. Revenue from Operations: Revenue for Q4FY26 was Rs 45,590 lakh, up 4.96% QoQ from Rs 43,434 lakh and up 18.76% YoY from Rs 38,389 lakh. The annual revenue for FY26 reached Rs 1,79,294 lakh, showing an increase of 9.24% from Rs 1,64,129 lakh in FY25. Net Profit / Loss: The company reported a consolidated net loss of Rs 2,368 lakh for Q4FY26, an improvement compared to a loss of Rs 2,945 lakh in Q3FY26 and a loss of Rs 4,134 lakh in Q4FY25. For FY26, the net loss widened to Rs 9,870 lakh from a loss of Rs 7,795 lakh in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs (2.57) and Rs (2.56) respectively. For FY26, the basic EPS stood at Rs (10.70). Standalone Financial Highlights: Total Income: Standalone total income for Q4FY26 was Rs 45,948 lakh, registering a QoQ increase of 12.71% from Rs 40,768 lakh and a YoY increase of 29.89% from Rs 35,375 lakh. The annual standalone total income for FY26 was Rs 1,71,571 lakh, up from Rs 1,53,667 lakh in FY25. Revenue from Operations: Standalone revenue for Q4FY26 stood at Rs 42,906 lakh, reflecting a growth of 10.14% QoQ from Rs 38,957 lakh and 25.80% YoY from Rs 34,107 lakh. Annual revenue for FY26 was Rs 1,63,354 lakh, a growth of 9.28% over Rs 1,49,478 lakh in FY25. Net Profit / Loss: The standalone result for Q4FY26 showed a turnaround with a net profit of Rs 2,735 lakh, compared to a net loss of Rs 2,000 lakh in Q3FY26 and a net loss of Rs 2,624 lakh in Q4FY25. However, For FY26, the company reported a net loss of Rs 566 lakh, which was lower than the loss of Rs 873 lakh in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs 2.96. For FY26, basic and diluted EPS was Rs (0.61). Business Highlights: Segment Performance: The company has only one primary reportable segment of activity, namely, Pharmaceuticals. Geographical Performance: India: Revenue from the Indian market for FY26 was Rs 89,413 lakh, compared to Rs 91,598 lakh in FY25. Outside India: Revenue from international markets for FY26 grew significantly to Rs 73,941 lakh, compared to Rs 57,880 lakh in FY25. Dividend: The Board of Directors has recommended a dividend of Rs 0.20 per equity share on a face value of Rs 2/- for the FY26. Exceptional Items: Exceptional items for FY26 included a consideration of Rs 346 lakh received for granting license rights to trademarks, a loss of Rs 213 lakh on sale and leaseback of non-current assets, and an impact of Rs 427 lakh (consolidated) / Rs 419 lakh (standalone) due to the implementation of the New Labour Codes. Labour Code Impact: The implementation of the four New Labour Codes resulted in an increase in gratuity liability and leave liability due to a change in the definition of "wages." International Presence: The company operates 10 manufacturing facilities (6 for Finished Dosage Forms and 4 for APIs) and maintains a presence in various therapeutic segments, including Gastro-intestinal, Respiratory, Anti-Infectives, and Cardiovascular. Aditi Panandikar, Managing Director, Indoco Remedies, said: “Revenue growth for the quarter and year was mainly driven by a good performance in the International Formulations Business, supported by a steady growth in the API & Services Businesses.” Result PDF

• Trendlyne
• 1 month 2 weeks ago

Indoco Remedies said it received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, 10 mg/mL

• Business Standard
• 4 months ago

Pharmaceuticals company Indoco Remedies announced Q3FY26 results Revenues are Rs 3,896 million, as against Rs 3,649 million, in Q3FY25, registering a 7% revenue growth. EBIDTA for the quarter is at Rs 259 million, compared to Rs 201 million in Q3FY25, registering a 29% growth. Aditi Panandikar, Managing Director, Indoco Remedies, said: “The revenue growth in this quarter is mainly due to the Export Formulations business and API business.” Result PDF

• Trendlyne
• 4 months 3 weeks ago